JPRN-jRCT2080220244未知3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy
ovartis Pharma K.K.0 个研究点目标入组 200 人开始时间: 2006年5月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Diagnosis of type 2 diabetes and treated with a stable dose of sulfonylurea
- •- Patients on diet and exercise who have not reached target blood glucose levels
- •- Outpatients
排除标准
- •- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •- Significant cardiovascular complications as defined by the protocol
- •- Significant diabetic complications as defined by the protocol
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
未知
1 期
To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220150ovartis Pharma K.K.264
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
未知
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220294ovartis Pharma K.K.370
已完成
4 期
Comparison of utility of Viladagliptin 50 mg tablet twice daily and metformin combination therapy with Vildagliptin 100 mg sustained release tablet once daily and metformin combination therapy in Indian patients with type 2 diabetes mellitus: A randomized open label phase IV clinical trialCTRI/2021/10/037574Dr Rudra Paul